Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collabor...

por Ibrahim, Jennifer, Underhill, Lisa H., Taylor, John S., Angell, Jennifer, Peterschmitt, M. Judith
Publicado 2016

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1

por Peterschmitt, M. Judith, Freisens, Selena, Underhill, Lisa H., Foster, Meredith C., Lewis, Grace, Gaemers, Sebastiaan J. M.
Publicado 2019

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry

por Mistry, Pramod K., Balwani, Manisha, Charrow, Joel, Kishnani, Priya, Niederau, Claus, Underhill, Lisa H., McClain, Monica R.
Publicado 2020

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial

por Pleat, Rebecca, Cox, Timothy M., Burrow, T. Andrew, Giraldo, Pilar, Goker-Alpan, Ozlem, Rosenbloom, Barry E., Croal, Laura R., Underhill, Lisa H., Gaemers, Sebastiaan J.M., Peterschmitt, M. Judith
Publicado 2016